Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of HIV-1 DNA and Ad5 Vaccines in East Africa
NCT00123968Phase 2Completed
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- May 2006
- Primary completion
- Jun 2012
- Modality
- Viral Vector Vaccines, DNA Vaccines
- Countries
- 3
01
Overview
Phase 2, randomised, double-blind trial of VRC-HIVDNA016-00-VP and VRC-HIVADV014-00-VP in human immunodeficiency virus infection (HIV) (6 arms), sponsored by National Institute of Allergy and Infectious Diseases. Primary endpoints: Local reactogenicity signs and symptoms, Systemic reactogenicity signs and symptoms and 4 more. Started May 2006; status: completed.
02
Drugs
VRC-HIVDNA016-00-VPVRC-HIVADV014-00-VP
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00123968.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00123968.